ACC 2020: Risk of Cardiovascular Mortality With ADT in Prostate Cancer
Posted: Wednesday, April 15, 2020
In patients with prostate cancer, the impact of androgen-deprivation therapy (ADT) on cardiovascular outcomes has been controversial. Neville Tan, MD, and colleagues from Western Health, Melbourne, Australia, conducted a systematic review and found that although patients treated with ADT appeared to have higher odds of myocardial infarction and cardiovascular mortality, the results were not significant. The findings were presented during the virtual 2020 American College of Cardiology (ACC) World Congress of Cardiology (Abstract 1466-151) and published in the Journal of the American College of Cardiology.
Using the MEDLINE and EMBASE databases, the researchers identified studies that included randomized controlled trials and cohort studies comparing patients with prostate cancer who received ADT and those who did not. Eligible studies included results on cardiovascular mortality or myocardial infarction and had a median follow-up of at least 1 year. Of the 5,197 studies identified, 14 met the inclusion criteria.
The studies included a total of 460,151 patients. About one-third of the patient pool (38.9%) was treated with ADT. Although the result was not statistically significant, the risk of cardiovascular mortality was higher among patients treated with ADT than in those who were not (P = .15). Similarly, the researchers found a 17% higher risk of myocardial infarction among patients who received ADT than in those who did not, although the difference again was not significant (P = .06).
“Further research may be needed to identify potential high-risk subgroups within the prostate cancer population that are more likely to suffer adverse cardiovascular outcomes,” the research team concluded.
Disclosure: The study authors reported no conflicts of interest.
